tradingkey.logo
搜尋

Impact Biomedical Inc

IBO
添加自選
0.472USD
+0.003+0.68%
收盤 07/02, 13:00美東報價延遲15分鐘
50.89M總市值
虧損本益比TTM

關於 Impact Biomedical Inc 公司

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc簡介

公司代碼IBO
公司名稱Impact Biomedical Inc
上市日期Sep 16, 2024
CEOHeuszel (Frank D)
員工數量2
證券類型Ordinary Share
年結日Sep 16
公司地址1400 Broadfield Blvd.
城市HOUSTON
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家United States of America
郵編77084
電話15852321500
網址https://www.impactbiomedinc.com/
公司代碼IBO
上市日期Sep 16, 2024
CEOHeuszel (Frank D)

Impact Biomedical Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
300.00K
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
300.00K
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%

常見問題

Impact Biomedical Inc的前五大股東是誰?

Impact Biomedical Inc的前五大股東如下:Mr. Mark Suseck

有多少機構持有Impact Biomedical Inc(IBO)的股份?

截至2026Q1,共有37家機構持有Impact Biomedical Inc的股份,合計持有的股份價值約為2.77M,占公司總股份的2.56% 。與2025Q4相比,機構持股有所增加,增幅為2084658.00。